Peter Stein, MD, deputy director, Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), FDA will present FDA’s keynote presentation at the CPhI North America conference on Thursday, April 26, 2018 in Philadelphia, PA. Dr. Stein joined FDA in late 2016 as the deputy director at the OND, CDER.

In 1999, he joined Bristol-Myers Squibb and later held various positions at Merck and Janssen, finishing his industry career at Merck as vice-president for Late-Stage Development in Diabetes and Endocrinology. During his industry career, Dr. Stein led development programs for several currently approved diabetes medications, and has worked on a range of programs from discovery through early and late clinical development.

He earned his medical degree from University of Pennsylvania and trained at Yale-New Haven Hospital in internal medicine, endocrinology, and metabolism. Stein was also on faculty at Yale in the Section of Endocrinology and served as the associate program director for the Primary Care Residency Program.  Additionally, he was the section chief for Endocrinology and the program director for the internal medicine residency program at the Medical College of Georgia. 

Dr. Stein is currently a clinical associate professor at the Robert Wood Johnson Medical School, where he once maintained an endocrinology practice.